MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jjcc.2025.02.012

Медицинская библиотека · Journal of cardiology · 2025

Implications of asymptomatic hypotension for patients prescribed sacubitril/valsartan: Insight from the REVIEW-HF registry.

Fujimoto Wataru, Matsumoto Shingo, Kanaoka Koshiro, Nasu Takahito, Kida Keisuke, Kagiyama Nobuyuki, Ishii Shunsuke, Watanabe Yukihiro, Kikuchi Atsushi, Ijichi Takeshi, Shibata Tatsuhiro, Tanaka Hidekazu

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Sacubitril/valsartan has unequivocally demonstrated prognostic improvement in patients with chronic heart failure in large-scale randomized controlled trials. However, it remains uncertain whether patients presenting with asymptomatic hypotension have distinct prognoses compared to those with symptomatic hypotension, and there is no consensus on the optimal strategy for managing asymptomatic hypotension.

METHODS AND

RESULTS

A multicenter retrospective study was conducted, analyzing data from patients initiated on sacubitril/valsartan therapy. The primary outcome was a composite of cardiovascular death or a hospitalization for heart failure. Among 992 patients, 72 patients (7.3 %) experienced symptomatic hypotension, and 122 patients (12.3 %) experienced asymptomatic hypotension within three months. The incidence of primary endpoint for patients who experienced hypotension, regardless of whether it was symptomatic or asymptomatic, was higher than for those who did not experience hypotension (Log-rank p < 0.05). Among patients who experienced asymptomatic hypotension, 23 patients discontinued sacubitril/valsartan within three days after the onset of asymptomatic hypotension. Patients who discontinued sacubitril/valsartan after the occurrence of asymptomatic hypotension experienced a significantly higher incidence of primary endpoints compared to those who continued sacubitril/valsartan therapy (Log-rank p = 0.01).

CONCLUSION

The prognosis of patients who discontinued sacubitril/valsartan after the occurrence of asymptomatic hypotension during sacubitril/valsartan therapy was poor. It may be beneficial to aim for the continuation of sacubitril/valsartan therapy even after the occurrence of asymptomatic hypotension.

Для цитирования: Fujimoto Wataru, Matsumoto Shingo, Kanaoka Koshiro, Nasu Takahito, Kida Keisuke, Kagiyama Nobuyuki, Ishii Shunsuke, Watanabe Yukihiro, Kikuchi Atsushi, Ijichi Takeshi, Shibata Tatsuhiro, Tanaka Hidekazu. Implications of asymptomatic hypotension for patients prescribed sacubitril/valsartan: Insight from the REVIEW-HF registry.. Journal of cardiology. 2025. DOI: 10.1016/j.jjcc.2025.02.012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.